tbuckley/cabot-search huggingface dataset:
AB0428 Cardiac Involvement in Systemic Sclerosis – A Portuguese Reality:
Authors: A.C. Duarte, I. Cordeiro, S. Sousa, L. Teixeira, A. Cordeiro, M.J. Santos
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Systemic sclerosis (SSc) has a wide spectrum of cardiovascular manifestations, being pulmonary hypertension (PH) one of the most lethal complications. Echocardiography is a pivotal screening test for patients at risk for PH that allows prompt identification of those with high estimated pulmonary artery systolic pressure (PASP). <h3>Objectives</h3> We conducted a retrospective analysis of patients with SSc followed in our Rheumatology department aiming to characterize those with estimated PASP≥35 mmHg. <h3>Methods</h3> Clinical and laboratory features, including dyspnea according to New York Heart Association (NYHA) classes, N-terminal pro-Brain Natriuretic Peptide (NT-proBNP) serum levels, uricemia, anti-nuclear antibody (ANA) specificities, 6-minute walk test (6MWT), and right heart catheterization (RHC), if required, were assessed. <h3>Results</h3> In total, 87 out of 103 SSc patients had available echocardiography results (females 93.1%; mean age 57.8 years; mean disease duration 10.3 years). Eight patients were classified as having NYHA class≥3. The median value of NTproBNP was 104 pg/mL (19 to 15902). Twenty one (24%) had estimated PASP≥35 mmHg (in 16 patients PASP could not be estimated), of whom16 performed RHC. PH (mPAP≥25 mmHg) was confirmed in 7 (44%) cases; 3 were classified as group 1, 1 as group 2, 2 as group 3 and 1 as group 5, according to the ERS/ECS 2013 classification. The group with elevated PASP included 11 patients with limited SSc, 7 with diffuse SSc, 1 sine scleroderma and 2 overlap syndromes. Comparison of patients with PASP≥35 mmHg with those with PASP&lt;35 mmHg put in evidence the following differences (Table bellow). <h3>Conclusions</h3> PASP is elevated in one quarter of SSc patients. This subgroup present more frequently higher NYHA classes, elevated NTproBNP levels and Scl70 positivity. About 44% of them had restrictive pulmonary disease. It is essential to closely monitor cardiorespiratory function in order to rule out cardiac involvement as early as possible. Our results suggest that there is still need to increase physicians9 awareness of systematic cardiovascular screening, since fewer patients than are nowadays recommended had a complete evaluation. <h3>Acknowledgement</h3> Cardiology department Hospital Garcia de Orta <h3>Disclosure of Interest</h3> None declared
Improved Detection of Minimal Residual Disease By Flow Cytometry in AML By Combining Manual Gating and Visne Clustering
Authors: Thomas Köhnke, Sandra Rechkemmer, Veit Leonhard Bücklein, Kristina Pfannes, Michael Fiegl, Karsten Spiekermann, Wolfgang Hiddemann, Marion Subklewe
Journal: Blood (2015)
SP0042 The Role of Imaging in The Management of Gout
Authors: M. Doherty
Journal: Annals of the Rheumatic Diseases (2016)

Identification of monosodium urate (MSU) crystals by microscopy remains the accepted gold standard for definitive diagnosis of gout. However, caveats include: suboptimal inter-observer agreement, lack of quantification of the extent of crystal deposition, and the impracticality of this method for diagnosis in primary care. In this presentation the pros and cons of different imaging methods for diagnosis, assessment and monitoring of gout will be discussed. Plain radiography is readily available and can show the extent of joint damage from gout, but changes usually occur late, are largely non-specific and sensitivity of detection is low. Computed tomography (CT) and helical CT allow detection and quantification of tophi and bone erosions and dual energy CT (DECT) allows detection (with high specificity) and quantification of size and number of subclinical tophi – these techniques may also be useful in diagnosing atypical gout syndromes (e.g. radiculopathy from axial tophi). MRI can also demonstrate tophi, joint damage and associated inflammation, though specificity is low and aspirate confirmation is usually required. Ultrasound (US) can demonstrate bone erosions, tophi and the double-contour sign and although the specificity of these findings has been questioned US is a widely available imaging technique in clinical practice. DECT and US show promise in being able to monitor reduction in tophus size on urate lowering therapy in clinical trials. Raman spectroscopy is an interesting newly applied technique that currently being explored. An important caveat to all imaging techniques is that they remain impractical in primary care where most gout patients are diagnosed and treated. Developing diagnostic methods that could be applied easily in this setting remains a priority. <h3>Disclosure of Interest</h3> None declared
High Dose Therapy with Autologous Blood Stem Cell Transplantation (Asct) for Relapsed, Follicular Lymphoma (FL) vs. De Novo, Diffuse Large B-Cell (dnDLBL) vs. Transformed, Follicular To Diffuse Large B-Cell Lymphoma (Tdlbl): No Difference in Freedom from Progression.
Authors: Brad Pohlman, Tony Jin, Kristie Summers, Elizabeth Kuczkowski, Stacey Brown, Matt Kalaycio, Ronald Sobecks, Steven Andresen, Laura Bernhard, Kelly Cherni, Janet Baker, Brian J. Bolwell
Journal: Blood (2004)
FRI0619-HPR Investigating The Effects of A Multidimensional Exercise Program on Symptoms and Antiinflammatory Status in Oa Patients of The Knee: Table.1.
Authors: E. Unal, P. Kısacık, S. Oksuz, G. Arın, O. Dogan, E. Karabulut
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Effects of exercise on pain, physical function, daily living activities and cytokines have been investigated in osteoarthritis (OA) patients (1). However there is no reported multidimensional approach including all these parameters at once in OA patients. On the other hand, the cognitive exercise therapy approach (BETY: Bilişsel Egzersiz Terapi Yaklaşımı) was used as a multidimensional exercise model including effects of improvements on symptoms and anti-inflammatory status in ankylosing spondylitis patients (2). <h3>Objectives</h3> The purpose of this study is to investigate the effects of a multidimensional (BETY) exercise program on symptoms and anti-inflammatory status in OA patients of the knee. <h3>Methods</h3> Forty patients with knee osteoarthritis defined as Kellgren-Lawrence (K-L) grade1 and 2, were included in this study, and divided randomly into two groups (BETY group and control). Health Assessment Questionnaire (HAQ), The Western Ontario and McMaster Universities Arthritis Index (WOMAC) was used for functional evaluation and IL-6 were analyzed for anti-inflammatory status in both groups. Control group did not get any exercise intervention. However, BETY group were participated to exercise sessions 3 times a week for 10 weeks. All measurements were repeated after 10 weeks in both groups. <h3>Results</h3> WOMAC pain, physical function and WOMAC total score values were decreased significantly (p&lt;0.05) in exercise group. However HAQ, WOMAC stiffness score were remained stable according to pretreatment values in this group (p&gt;0.05). Although any significant change in IL-6 in both groups were not observed, IL-6 decreased in BETY group. Moreover, TNF-a showed significant increase in control group (p&lt;0.05). No change was observed for other values between pre- and post-treatment in control group (p&gt;0.05). There was no difference between two groups after 10 weeks (p&gt;0.05). <h3>Conclusions</h3> This study is an original study in terms of analyzing exercise-induced TNF-a and IL-6 relationship in OA patients of the knee. We concluded that BETY program did not cause negative effects in OA patients. BETY should be taken into consideration as a multidimensional exercise program for OA patients. <h3>References</h3> Zhang, S.L., Liu, H.Q., Xu, X.Z., Zhi, J., Geng, J.J. Effects of exercise therapy on knee joint function and synovial fluid cytokine levels in patients with knee osteoarthritis. Mol. Med. Report. 2013;(7):183–186. Kisacik, P., Unal, E., Akman, U., Yapali, G., Karabulut, E., Akdogan, A. Investigating the effects of a multidimensional exercise program on symptoms and antiinflammatory status in female patients with ankylosing spondylitis. Comp Ther&amp;Clin Pract 2016;(22):38–43. <h3>Disclosure of Interest</h3> None declared
A Prospective, Observational Study of the Effectiveness and Safety of a Weekly Fixed Dose of Darbepoetin alfa with Current Practice Iron Management for the Treatment of Chemotherapy-Induced Anemia (CIA): A Subanalysis in Patients (pts) with Lymphoproliferative Malignancies (LPM).
Authors: A. Alegre, A. Salar, I. Roig, J.C. Bermejo, A. Palacios, R. de Paz, R. Arranz, A. Fernández, R. Calzada, P. Iturralde
Journal: Blood (2005)
Clinical Efficacy and Feasibility of an Intensive Preparative Regimen with Busulfan, Cyclophosphamide, and Total Body Irradiation Followed by Allogeneic Stem Cell Transplantation for Patients with Myeloid Malignancies.
Authors: Shingo Yano, Osamu Asai, Nobuaki Dobashi, Hiroshi Osawa, Yutaka Takei, Yuichi Yahagi, Shinobu Takahara, Yoji Ogasawara, Hiroko Otsubo, Yuko Yamaguchi, Jiro Minami, Dai Maruyama, Tatsunosuke Kobayashi, Yasutaka Hoshi, Noriko Usui
Journal: Blood (2006)
Immunohistochemical Prognostic Marker for Diffuse Large B Cell Lymphoma in Patients Treated with CHOP Like Chemotherapy: Validation of the Algorithm by Hans Et Al. and Analysis of Individual Markers
Authors: Cheolwon Suh, Jooryung Huh, Sukjoong Oh, Jeong-Hyeon Jo, Shin Kim, Joon Khang
Journal: Blood (2008)
OC-046 The ACPGBI/BSG Complex Colorectal Polyp Minimum Dataset: An Update
Authors: A Chattree, J Barbour, MD Rutter
Journal: Gut (2016)

<h3>Introduction</h3> Variation in the assessment of large non-pedunculated colorectal polyps (LNPCPs) appears to lead to variable and suboptimal management outcomes.<sup>1</sup> Multidisciplinary discussion has been advocated to optimise management. Our ACPGBI/BSG evidence-based, expert consensus minimum dataset developed in 2014–15 has been felt to enhance LNPCP assessment and decision making.<sup>2</sup> We propose that further refinement will ensure increased robustness. <h3>Methods</h3> A 14 person ACPGBI/BSG approved multidisciplinary panel reassessed the original minimum dataset using Delphi consensus methodology. A subcommittee tested the proforma dataset’s applicability and usability for multidisciplinary discussion over 20 LNPCP cases. This process was intended to find any previously unidentified patient and polyp factors that may influence management. Proposed additional parameters were then subject to voting with &gt;80% agreement required for consensus. The updated dataset was then assessed with a further 20 LNPCP cases. <h3>Results</h3> 8 new parameters considered helpful for LNPCP assessment were identified. Whilst patient parameters such as symptoms, treatment preferences and comorbidity had previously been identified, it was agreed that establishing patient amenability to undergo treatment at another hospital was important and may potentially increase available therapeutic options. With regards to lesion characteristics, it was felt that specification of the ‘SMSA scoring system’ encouraged more comprehensive and standardised lesion assessment of the complexity of lesion endoscopic resectability.<sup>2</sup> Comprehensive photodocumentation was also considered necessary with parameters agreed relating to the capture of morphology and surface features and specific rectal imaging. Further piloting of the revised dataset identified no further required parameters (see figure). <h3>Conclusion</h3> The development of an ACPGBI/BSG minimum dataset allows for comprehensive and standardised multidisciplinary LNPCP assessment. It forms part of a structured ACPGBI/BSG management framework for LNPCPs, also comprising guidelines and key performance indicators. In addition to facilitating multidisciplinary discussion, the dataset can also serve as an aide memoire to guide detailed endoscopic assessment. The updated consensus process ensures that all factors pertinent to decision making are included whilst applicability and usability are confirmed following further piloting. <h3>References</h3> 1 Chattree A, Painter J, Silcock J, <i>et al</i>. Marked Variation in Endoscopic Mucosal Resection Outcomes within the UK Bowel Cancer Screening Programme. <i>United European Gastroenterology Journal</i> 2015;<b>2</b>(Supp 1) 2 Rutter MD, Chattree A, Barbour J, <i>et al</i>. BSG/ACPGBI Guidelines for the management of large non pedunculated colorectal polyps. <i>Gut</i> 2015;<b>0</b>:1–27 <h3>Disclosure of Interest</h3> None Declared
AB0983 What Is The Fastest Route for Patients with Inflammatory Arthritis To Early Arthritis Clinic
Authors: A.M. Al Marzooqi, J. Al Saleh
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Patient self-referral to a rheumatologist, without any former visit to the general practitioner (GP), was shown to be a significant contributing factor in delivering the optimal care for patients with early arthritis [1]. The literature has limited data on the referral of patients with early arthritis by secondary care specialities to rheumatologists. This abstract compares the time required for patients with inflammatory arthritis to access the rheumatology clinic when referred by different specialities. <h3>Methods</h3> We reviewed the medical records and electronic files of all patients with synovitis who attended our rheumatology clinic between 1st June 2012 and 1st June 2015. The following data was captured; demographics, time lag between onset of symptoms and the first rheumatologist consultation, date of referral, and the speciality of the referring physician. We stratified the patients according to the source of referral into two groups; GP referral and specialist referral. Data are presented as the median values and interquartile range (IQR). Mann-Whitney test was used to compare the two groups. <h3>Results</h3> We identified 173 patients with inflammatory arthritis. 134 (77.5%) were Emirati9s, 137 (79.2%) were females, and median age was 41 (IQR 34–52 years). 91 (52.6%) patients were referred by a GP. The median delay from the onset of symptoms to assessment by a rheumatologist for patients referred by GP was 214 days (IQR 59–722). Whereas, for those referred by secondary care specialities was 95 days (IQR 31–372). This difference was statistically significant (Z-Score =2.4655, p-value &lt;0.01). The fastest referral was through accident and emergency department 63 days (IQR 5–185). <h3>Conclusions</h3> In our population, patients with early arthritis were referred faster to the rheumatology clinic by a secondary care specialist rather than the GP. <h3>References</h3> Fautrel B, et al. Rheumatology 2010; 49:1 47–155. <h3>Disclosure of Interest</h3> None declared
A Phase II Study of the Efficacy and Safety of an Intensified Schedule of Azacitidine (AZA) in Intermediate-2 and High Risk MDS Patients: A Study By the Groupe Francophone Des Myelodysplasies (GFM)
Authors: Lionel Ades, Agnes Guerci-Bresler, Pascale Cony-Makhoul, Laurence Legros, Marie Sebert, Thorsten Braun, Jacques Delaunay, Benedicte Samey, Kristell Desseaux, Sylvie Chevret, Pierre Fenaux
Journal: Blood (2015)
Human kallikrein 13: Evaluation of its role in the degradation of extracellular matrix proteins and characterization of its substrate specificity
Authors: Shahriar Koochekpour, Oliver Sartor, Francine Hebert, Tae-Jin Lee, Konrad Sandhoff, Natascha Remmel, Ardalan Minokadeh, David Y. Patten
Journal: Cancer Research (2004)

Proc Amer Assoc Cancer Res, Volume 45, 2004

1818 

In prostate cancer, as in other malignancies, the complex multi-step process of cancer invasion and metastasis involves both tumor and stromal cells interacting in a complex microenvironment. Migration and invasion are cellular events that require the participation of proteolytic enzymes such as matrix metalloproteinases (MMPs), urokinase plasminogen activator (uPA), and Cathepsin D. Identification and characterization of molecular regulators of these proteases, and their pathways, are of critical importance in developing strategies designed to better control prostate cancer in the patient. Using a novel cloning strategy in our laboratory, we identified prosaposin as a secreted protein in a poorly differentiated androgen-independent prostate cancer cell line (PC-3). The studies reported herein continue our efforts to characterize the role of saposin C/prosaposin in prostate carcinogenesis and in the metastatic process. Prosaposin is the lysosmal precursor of four homologous sphingolipid activator proteins (saposin A-D) and also functions as a secretory protein with neurotrophic activities. The neurotrophic activity of prosaposin has been located at the amino-terminal portion of saposin C. We found a higher expression of prosaposin or saposin C in prostate stromal cells and androgen-independent prostate cancer cells-(PC-3 and DU-145) than in androgen-dependent LNCaP cells or normal prostate epithelial cells. Using in vitro invasion assay, saposin C stimulates migration and invasion of prostate cancer and stromal cells. To understand the underlying molecular mechanisms, we evaluated saposin C’s effects on the expression or activity of matrix-degrading enzymes (MMPs, uPA, and Cathepsins). Saposin C upregulated the uPA/uPAR and Cathepsin D mRNA and protein (both cellular and secreted forms) expression in these cells. In contrast, using immunoblotting and gelatin zymography, the expression or enzymatic activities of MMP-2 and –9 were not affected. Prostate stromal cell response in the above assays suggests that saposin C, acting via paracrine loops, may act as a potential mediator of tumor-stromal interaction in prostate cancer. Normal prostate epithelial cells were not responsive to saposin C treatment in this study. Our findings for the first time documented a novel regulatory role for saposin C (or prosaposin) in motility, invasion, and expression of uPA/uPAR/Cathepsin D in prostate cancer and stromal cells. Through these effects, saposin C may contribute to the invasive or metastatic potential of prostate cancer. Supported by Stanley S. Scott Cancer Center, Louisiana State University-Health Sciences Center.
DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling
Authors: Olga A Guryanova, Kaitlyn Shank, Barbara Spitzer, Luisa Luciani, Richard P Koche, Francine E Garrett-Bakelman, Chezi Ganzel, Benjamin H Durham, Abhinita Mohanty, Gregor Hoermann, Sharon A Rivera, Alan G Chramiec, Elodie Pronier, Lennart Bastian, Matthew D Keller, Daniel Tovbin, Evangelia Loizou, Abby R Weinstein, Adriana Rodriguez Gonzalez, Yen K Lieu, Jacob M Rowe, Friederike Pastore, Anna Sophia McKenney, Andrei V Krivtsov, Wolfgang R Sperr, Justin R Cross, Christopher E Mason, Martin S Tallman, Maria E Arcila, Omar Abdel-Wahab, Scott A Armstrong, Stefan Kubicek, Philipp B Staber, Mithat Gönen, Elisabeth M Paietta, Ari M Melnick, Stephen D Nimer, Siddhartha Mukherjee, Ross L Levine
Journal: Nature Medicine (2016)
The Combination of Bortezomib and Rituximab Is Effective and Safe in Relapsed/Refractory Indolent Non Follicular and Mantle-Cell Non Hodgkin Lymphoma: a Phase II Multicenter Study by Intergruppo Italiano Linfomi.
Authors: Annalisa Chiappella, Patrizia Pregno, Pier Luigi Zinzani, Fabio Facchetti, Andrea Evangelista, Alberto Fabbri, Andres JM Ferreri, Silvia Franceschetti, Roberto Freilone, Livio Gargantini, Daniela Gioia, Anna Marina Liberati, Lorella Orsucci, Luigi Rigacci, Eleonora Russo, Vittorio Stefoni, Alessandra Tucci, Umberto Vitolo
Journal: Blood (2009)
The Novel, Orally Available Multi-Kinase Inhibitor BAY 73-4506 in Multiple Myeloma
Authors: Iris Breitkreutz, Marc S Raab, Olaf Christensen, Alexander Zimmerhackl, Jing Zhang, Simona Blotta, Teru Hideshima, Dharminder Chauhan, Scott Wilhelm, Kenneth C Anderson, Klaus Podar
Journal: Blood (2008)
Dynamics of BCR-ABL Kinase Domain Mutations in Patients with Chronic Myeloid Leukemia (CML) after Treatment with One, Two or Three Tyrosine Kinase Inhibitors (TKI).
Authors: Elias Jabbour, Dan Jones, Hagop Kantarjian, Susan O’Brien, Guillermo Garcia-Manero, Francis Giles, William Wierda, Jorge Cortes
Journal: Blood (2006)
In Vitro Synergistic Anti-Tumor Activity by Targeting TRAIL-R1 and CD20 Antigen by Combining HGS-ETR1 (Agonistic Human Monoclonal Antibody to TRAIL Receptor 1) and Rituximab Monoclonal Antibody Against Non-Hodgkin’s Lymphoma Cells (NHL).
Authors: Myron S. Czuczman, Sreeram Maddipatla, Joy Knight, Francisco J. Hernandez-Ilizaliturri
Journal: Blood (2005)
ALK Rearrangements in Non-Small Cell Lung Cancer : Comprehensive Integration of Genomic, Gene Expression and Protein Analysis
Authors: Johanna S. M. Mattsson, Maria A. Svensson, Bjorn Hallström, Hirsh Koyi, Eva Branden, Hans Brunnström, Karolina Edlund, Simon Ekman, Linnea La Fleur, Marianna Grinberg, Joerg Rahnenfuehrer, Karin Jirström, Fredrik Ponten, Mats G. Karlsson, Christina Karlsson, Gisela Helenius, Mathias Uhlen, Johan Botling, Patrick Micke
Journal: Journal of Thoracic Oncology (2015)
Novel Dombrock Blood Group Genetic Variants in Different Ethnic Groups Identified by High Throughput Beadchip DNA Analysis.
Authors: Marion E. Reid, Prabhakar Vissavajjhala, Poosub Palacajornsuk, Randall W. Velliquette, Asok Chaudhuri, Ghazala P. Hashmi, Tasmia Shariff, Michael Seul
Journal: Blood (2004)
AB0445 Ocular Posterior Segment Findings in Antiphospholipid Syndrome
Authors: E. Kucukkomurcu, A.U. Unal, F. Esen, G. Ozen, H. Diresekeneli, H. Kazokoglu
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Antiphospholipid Syndrome (APS) can affect all vessels in the body. Ocular complications are seen most commonly in posterior segment of the eye in these patients. The purpose of this study is to evaluate the posterior segment signs in APS patients and to compare these signs between Primary APS, Secondary APS and Systemic Lupus Erythematosus (SLE) patients without APS. <h3>Methods</h3> We have included 11 Primary APS, 2 Sjogren9s Syndrome/ 27 SLE patients diagnosed as Secondary APS and 29 SLE patients without APS followed at Marmara University, Division of Rheumatology Outpatient Clinics in this study. All of the patients had a detailed ophthalmological examination, including dilated fundus examination and color fundus imaging. 10 patients with Primary Antiphospholipid Syndrome, 23 patients with Secondary APS and 23 patients with SLE had fundus fluorescein angiography imaging. <h3>Results</h3> Mean age of the patients was 34.8±12.5 years in Primary APS, 38.3±11.1years in Secondary APS and 38.3±10.9 years in SLE group. In Primary APS 45.5% of patients had venous thrombosis, 45.5% had arterial thrombosis and 72.7% had obstetric complications. In Secondary APS, 44.8% patients had venous thrombosis, 27.6% had arterial thrombosis and 72.4% had obstetric complications. Venous tortuosity was observed in 6 eyes of 3 patients in Primary APS group and 8 eyes of 4 patients in Secondary APS group. One patient with Secondary APS had bilateral branch retinal arterial occlusion. The most common ocular finding of the FFA was pigment epithelial window defect and was observed totally in 19 eyes of 12 patients. There was no statistically significant difference of ocular findings between the Primary APS, Secondary APS and SLE patients. <h3>Conclusions</h3> In this study, ocular posterior segment findings of Primary APS had been observed less commonly than previous studies. The lower prevalence of ocular complications in this study can be the result of early diagnosis and better control of relapses in these patients. <h3>Disclosure of Interest</h3> None declared